Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye



    SYDNEY, Nov. 7 /CNW/ - In the Lancet, on Tuesday November, 6th new
results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
2007 clinical trial have been published and presented on the same date at a
press conference held during the AHA.

    
    -   First lipid modifying agent shown to reduce the need for treatment of
        the leading causes of blindness and deteriorating vision in patients
        with type 2 diabetes

    -   Reduces need for laser treatment in patients with and without known
        diabetic retinopathy

    -   Significantly decreases progression of diabetic eye disease
    

    If you are interested in knowing more about this breaking news and in
getting additional information on the management of microvascular
complications in type 2 diabetes, we are pleased to invite you to visit "the
Field Study Investigators Website", where you will have the opportunity to
login to the Webcast of the press conference.

    Please click below: http://www.thefieldtrial.org





For further information:

For further information: Media Contact: Beth Quinlivan, University of
Sydney, Ph: +61-2-9036-6528, Mob: +61-0-419-229-134,
bquinlivan@med.usyd.edu.au

Organization Profile

NHMRC CLINICAL TRIALS CENTRE - THE UNIVERSITY OF SYDNEY

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890